Please login to the form below

Not currently logged in
Email:
Password:

Merck Serono’s Enrica Alteri appointed head of safety and efficacy at EMA

Will play key role in introduction of pharmacovigilance legislation

Enrica Alteri - EMAThe European Medicines Agency (EMA) has appointed Merck Serono's Enrica Alteri as its new head of safety and efficacy of medicines.

In her new position she will play a leading role in the application of the EMA's new pharmacovigilance legislation, which introduces new rules governing the monitoring, identification and assessment of adverse events caused by drugs.

Dr Alteri was most recently head of risk management and epidemiology at Merck Serono's soon to be closed Swiss headquarters in Geneva, and takes over from Francesco Pignatti, the EMA's head of oncology.

Pignatti had been acting head of safety and efficacy of medicines since March, 2012, following the departure of Xavier Luria.

Dr Alteri has many years of experience in drug safety having served as director of pharmacovigilance at Serono, before its acquisition by Merck KGaA.

She has also spent time working in medical safety teams at both Novartis and Ciba, and was involved in developing the safety profiles of such products as Coartem/Riamet, which is the World Health Organization's (WHO) recommended first-line treatment against malaria.

She has also previously served as a member of the European Course of Pharmaceutical Medicine faculty (ECPM) in Basel, Swtizerland, and was part of the Council for International Organizations of Medical Sciences (CIOMS) working group on pharmacovigilance in resource-poor countries.

4th July 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Using human insights to push healthcare communications forward
This blog highlights the value of human perspectives, showing how insights can propel healthcare communications forward to ultimately improve lives...
RWE Blog 4: The place of real-world evidence in the market access strategy
The fourth and final blog in our latest series focuses on market access strategy. This follows our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in...
RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...

Infographics